Redox control of prion and disease pathogenesis

Antioxidants and Redox Signaling

Volumn 12, Issue 11, 2010, Pages 1271-1294

  Singh, Neena ^a   Singh, Ajay ^a   Das, Dola ^a   Mohan, Maradumane L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (N METHYL N PROPARGYAMINOMETHYL) 8 HYDROXYQUINOLINE; 5 4 (2 HYDROXYETHYL)PIPERAZIN 1 YL(METHYL) 8 HYDROXYQUINOLINE; ANTIOXIDANT; CANNABIDIOL; CHELATING AGENT; CLIOQUINOL; COPPER; DEFEROXAMINE; EUK 189; FLUPIRTINE; IRON; PRION PROTEIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; BETA SHEET; BINDING AFFINITY; BRAIN LEVEL; CARBOXY TERMINAL SEQUENCE; CHELATION THERAPY; CONFORMATIONAL TRANSITION; DISEASE COURSE; HOMEOSTASIS; HUMAN; IRON CHELATION; METAL METABOLISM; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW;

ANIMALS; HUMANS; OXIDATION-REDUCTION; PRION DISEASES; PRIONS;

EID: 77951868857     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2628     Document Type: Review

References (254)

1. Abid K and Soto C. The intriguing prion disorders. Cell Mol Life Sci 63: 2342-2351, 2006.
2. Aguzzi A and Polymenidiou M. Mammalian prion biology: one century of evolving concepts. Cell. 116: 313-327, 2004.
3. Aguzzi A, Sigurdson C, and Heikenwaelder M. Molecular mechanisms of prion pathogenesis. Annu Rev Pathol Mech Dis 3: 11-40, 2008.
4. Allsop D, Mayes J, Moore S, Masad A, and Tabner BJ. Metal-dependent generation of reactive oxygen species from amyloid proteins implicated in neurodegenerative disease. Biochem Soc Trans 36: 1293-1298, 2008.
5. Andreoletti O, Levavasseur E, Uro-Coste E, Tabouret G, Sarradin P, Delisle MB, Berthon P, Salvayre R, Schelcher F, and Negre-Salvayre A. Astrocytes accumulate 4-hydro-xynonenal adducts in murine scrapie and human Creutz-feldt-Jakob disease. Neurobiol Dis 11: 386-393, 2002.
6. Arlt S, Kontush A, Zerr I, Buhmann C, Jacobi C, Schröter A, Poser S, and Beisiegel U. Increased lipid peroxidation in cerebrospinal fluid and plasma from patients with Creutzfeldt-Jakob disease. Neurobiol Dis 10: 150-156, 2002.
7. 2\+ binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 39: 13760-13771, 2000.
8. Atarashi R, Moore RA, Sim VL, Hughson AG, Dorward DW, Onwubiko HA, Priola SA, and Caughey B. Ultrasensitive detection of scrapie prion protein using seeded conversion of recombinant prion protein. Nat Methods 4: 645-650, 2007.
9. Barnham KJ and Bush AI. Metals in Alzheimer's and Parkinson's diseases. Curr Opin Chem Biol 12: 222-228, 2008.
10. Barnham KJ, Cappai R, Beyreuther K, Masters CL, and Hill AF. Delineating common molecular mechanisms in Alzheimer's and prion diseases. Trends Biochem Sci 31: 465-472, 2006.
11. Bartzokis G. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psychiatry 35: 480-487, 1994.
12. Sc in cells and infectious brain homogenate by redox-iron: implications for prion replication and disease pathogenesis. Mol Biol Cell 18: 3302-3312, 2007.
13. Bayer TA, Schäfer S, Breyhan H, Wirths O, Treiber C, and Multhaup G. A vicious circle: role of oxidative stress, in-traneuronal Abeta and Cu in Alzheimer's disease. Clin Neuropathol 25: 163-171, 2006.
14. Beard JL and Connor JR. Iron status and neural functioning. Annu Rev Nutr 23: 41-58, 2003.
15. Beard JL. Why iron deficiency is important in infant development. J Nutr 138: 2534-2536, 2008.
16. Behl C, Davis JB, Lesley R, and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827, 1994.
17. Bellingham SA, Coleman LA, Masters CL, Camakaris J, and Hill AF. Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. J Biol Chem 284: 1291-1301, 2009.
18. Beranger F, Crozet C, Goldsborough A, and Lehman S. Trehalose impairs aggregation of PrPsc molecules and protects prion-infected cells against oxidative damage. Biochem Biophys Res Commun 374: 44-48, 2008.
19. Bieschke J, Weber P, Sarafoff N, Beekes M, Giese A, and Kretzschmar H. Autocatalytic self-propagation of misfolded prion protein. Proc Natl Acad Sci USA 101: 12207-12211, 2004.
20. Bio KF, Dal Pizzol F, Conte da Frota ML, Walz R, Andrades ME, da Silva EG, Brentani RR, Izquierdo I, and Fonseca Moreira JC. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med 30: 1137-1144, 2001.
21. Bocharova OV, Breydo L, Salnikov VV, and Baskakov IV. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 44: 6776-6787, 2005.
22. Bounhar Y, Zhang Y, Goodyer CG, and LeBlanc A. Prion protein protects human neurons against Bax-mediated ap-optosis. J Biol Chem 276: 39145-39149, 2001.
23. Brazier MW, Davies P, Player E, Marken F, Viles JH, and Brown DR. Manganese binding to the prion protein. J Biol Chem 283: 12831-12839, 2008.
24. Brazier MW, Doctrow SR, Masters CL, and Collins SJ. A manganese-superoxide dismutase=catalase mimetic extends survival in a mouse model of human prion disease. Free Radic Biol Med 45: 184-192, 2008.
25. Brazier MW, Lewis V, Ciccotosto GD, Klug GM, Lawson VA, Cappai R, Ironside JW, Masters CL, Hill AF, White AR, and Collins S. Correlative studies support lipid peroxida-tion is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res Bull 68: 346-354, 2006.
26. Brown DR and Besinger A. Prion protein expression and superoxide dismutase activity. Biochem J 334: 423-429, 1998.
27. Brown DR, Clive C, and Haswell SJ. Antioxidant activity related to copper binding of native prion protein. J Neu-rochem 76: 69-76, 2001.
28. Brown DR, Hafiz F, Glassmith LL, Wong BS, Jones IM, Clive C, and Haswell SJ. Consequences of manganese replacement of copper for prion protein function and pro-teinase resistance. EMBO J 19: 1180-1186, 2000.
29. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R, Fraser PE, Kruck T, von Bohlen A, Schulz-Schaeffer W, Giese A, Westaway D, and Kretzschmar H. The cellular prion protein binds copper in vivo. Nature 390: 684-687, 1997.
30. Brown DR, Schmidt B, and Kretzschmar HA. Effects of copper on survival of prion protein knockout neurons and glia. J Neurochem 70: 1686-1693, 1998.
31. Brown DR, Schultz-Schaeffer WJ, Schmidt B, and Kretzschmar HA. Prion protein deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp Neurol 146: 104-112, 1997.
32. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, and Jones M. Normal prion protein has an activity like that of super-oxide dismutase. Biochem J 344: 1-5, 1999.
33. Brown DR. Prion protein expression aids cellular uptake and veratridine-induced release of copper. J Neurosci Res 58: 717-725, 1999.
34. Sc-like prion protein peptide inhibits the function of cellular prion protein. Biochem J 352: 511-518, 2000.
35. Brown LR and Harris DA. Copper and zinc cause delivery of the prion protein from the plasma membrane to a subset of early endosomes and the Golgi. J Neurochem 87: 353-363, 2003.
36. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S, Fraser H, and Bostock CJ. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature 389: 498-501, 1997.
37. Büeler H, Aguzzi A, Sailer A, Greiner RA, Autenried P, Auget M, and Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 73: 1339-1347, 1993.
38. Bush AI and Tanzi RE. Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5: 421-432, 2008.
39. Castilla J, Saá P, Hetz C, and Soto C. In vitro generation of infectious scrapie prions. Cell 121: 195-206, 2005.
40. Caughey B and Baron GS. Prions and their partners in crime. Nature. 443: 803-810, 2006.
41. Caughey B. Race RE, Ernst D, Buchmeier MJ, and Chesebro B. Prion protein biosynthesis in scrapie-infected and unin-fected neuroblastoma cells. J Virol 63: 175-181, 1989.
42. Chacón MA, Barŕia MI, Lorca R, Huidobro-Toro JP, and Inestrosa NC. A human prion protein peptide [PrP(59-91)] protects against copper neurotoxicity. Mol Psychiatry 8: 853-862, 2003. (Pubitemid 37346540)
43. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey B, Masliah E, and Oldstone M. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 308: 1435-1439, 2005.
44. Chiesa R and Harris DA. Prion diseases: what is the neu-rotoxic molecule? Neurobiol Dis 8: 743-763, 2001.
45. Chinta SJ and Andersen JK. Redox imbalance in Parkinson's disease. Biochim Biophys Acta 1780: 1362-1367, 2008.
46. Choi CJ, Anantharam V, Saetveit NJ, Houk RS, Kanthasamy A, and Kanthasamy AG. Normal cellular prion protein protects against manganese-induced oxidative stress and apoptotic cell death. Toxicol Sci 98: 495-509, 2007.
47. Choi YG, Kim JI, Lee HP, Jin JK, Choi EK, Carp RI, and Kim YS. Induction of heme oxygenase-1 in the brains of scrapie-infected mice. Neurosci Lett 289: 173-176, 2000.
48. Choi CJ, Kanthasamy A, Anantharam V, Kanthasamy AG. Interaction of metals with prion protein: possible role of divalent cations in the pathogenesis of prion diseases. Neurotoxicology 27: 777-787, 2006.
49. Cohen FE, Pan KM, Huang Z, Baldwin M, Fletterick RJ, and Prusiner SB. Structural clues to prion replication. Science 264: 530-531, 1994.
50. Collinge J, Sidle KCL, Meads J, Ironside J, and Hill AF. Molecular analysis of prion strain variation and the aetiology of "new variant" CJD. Nature 383: 685-690, 1996.
51. Cook CI and Yu BP. Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Dev 102: 1-13, 1998.
52. Davies P and Brown DR. The chemistry of copper binding to PrP: is there sufficient evidence to elucidate a role for copper in protein function? Biochem J 410: 237-244, 2008.
53. DeArmond SJ and Ironside JW. Neuropathology of prion diseases. In: Prion biology and diseases, edited by Prusiner SB. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999, pp. 585-652.
54. Deleault NR, Harris BT, Rees JR, and Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104: 9741-9746, 2007.
55. Dirikoc S, Priola SA, Marella M, Zsurger N, and Chabry J. Nonpsychoactive Cannabidol prevents prion accumulation and protects neurons against prion toxicity. J Neurosci 27: 9537-9544, 2007.
56. Doherr MG. Brief review on the epidemiology of transmissible spongiform encephalopathies (TSE). Vaccine 25: 5619-5624, 2007.
57. Dukhande VV, Malthankar-Phatak GH, Hugus JJ, Daniels CK, and Lai JC. Manganese-induced neurotoxicity is differentially enhanced by glutathione depletion in astro-cytoma and neuroblastoma cells. Neurochem Res 11: 1349-1357, 2006.
58. El-Youssef M. Wilson disease. Mayo Clin Proc 78: 1126-1136, 2003.
59. Fasano C, Campana V, and Zurzolo C. Prions: protein only or something more? Overview of potential prion cofactors. J Mol Neurosci 29: 195-214, 2006.
60. Fernaeus S and Land T. Increased iron-induced oxidative stress and toxicity in scrapie-infected neuroblastoma cells. Neurosci Lett 382: 133-136, 2005.
61. Fernaeus S, Halldin J, Bedecs K, and Land T. Changed iron regulation in scrapie-infected neuroblastoma cells. Brain Res Mol Brain Res 133: 266-273, 2005.
62. Flechsig E, Shmerling D, Hegyi I, Raeber AJ, Fischer M, Cozzio A, von Mering C, Aguzzi, A, and Weissmann C. Prion protein devoid of the octapeptide repeat region restores susceptibility to scrapie in PrP knockout mice. Neuron 27: 399-408, 2000.
63. Floyd RA and Hensley K. Oxidative stress in brain aging: implications for therapeutics of neurodegenerative diseases. Neurobiol Aging 23: 795-807, 2002.
64. Freixes M, Rodŕiguez A, Dalfó E, and Ferrer I. Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol Aging 27: 1807-1815, 2006.
65. Gaeta A and Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146: 1041-1059, 2005.
66. Gains MJ and LeBlanc AC. Canadian Association of Neu-rosciences Review: prion protein and prion diseases: the good and the bad. Can J Neurol Sci 34: 126-145, 2007.
67. Gambetti P, Dong Z, Yuan J, Xiao X, Zheng M, Alshekhlee A, Castellani R, Cohen M, Barria MA, Gonzalez-Romero D, Belay ED, Schonberger LB, Marder K, Harris C, Burke JR, Montine T, Wisniewski T, Dickson DW, Soto C, Hulette CM, Mastrianni JA, Kong Q, and Zou WQ. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 63: 697-708, 2008.
68. Gerlach M, Ben-Shachar D, Riederer P, and Youdim MB. Altered brain metabolism of iron as a cause of neurode-generative diseases. J Neurochem 63: 793-807, 1994.
69. Goldberg MS and Lansbury PT Jr. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2: E115-E119, 2000.
70. Gregory A and Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol 43: 286-296, 2005.
71. Gu Y, Hinnerwisch J, Fredricks R, Kalepu S, Mishra RS, and Singh N. Identification of cryptic nuclear localization signals in the prion protein: implications for prion disease pathogenesis. Neurobiol Dis 12: 133-149, 2003.
72. Gu Y, Luo X, Basu S, Fujioka H, and Singh N. Cell-specific metabolism and pathogenesis of transmembrane prion protein. Mol Cell Biol 26: 2697-2715, 2006.
73. Gu Y, Singh A, Bose S, and Singh N. Pathogenic mutations in the glycosylphosphatidylinositol signal peptide of PrP modulate its membrane topology in neuroblastoma cells. Mol Cell Neurosci 37: 647-656, 2007.
74. Gu Y, Verghese S, Bose S, Mohan ML, and Singh N. Mutant prion protein D202N associated with familial prion disease forms "curly" intracellular aggregates and sensitizes cells to oxidative stress. J Mol Neurosci 32: 90-96, 2007.
75. Gu Y, Verghese S, Mishra RS, Xu X, Shi Y, and Singh N. Mutant prion protein-mediated aggregation of normal prion protein in the endoplasmic reticulum: implications for prion propagation and neurotoxicity. J Neurochem 84: 10-22, 2003.
76. Guentchev M, Siedlak SL, Jarius C, Tagliavini F, Castellani RJ, Perry G, Smith MA, and Budka H. Oxidative damage to nucleic acids in human prion disease. Neurobiol Dis 9: 275-281, 2002.
77. Guentchev M, Voigtlander T, Haberler C, Groschup MH, and Budka H. Evidence for oxidative stress in experimental prion disease. Neurobiol Dis 7: 270-273, 2000.
78. Gutteridge JM. The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts. FEBS Lett 150: 454-458, 1982.
79. Harris DA and True HL. New insights into prion structure and toxicity. Neuron. 50: 353-357, 2006.
80. Hashimoto M, Hsu LJ, Xia Y, Takeda A, Sisk A, Sundsmo M, and Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP=alpha-synuclein in vitro. Neuroreport 10: 717-721, 1999.
81. Hegde RS and Rane NS. Prion protein trafficking and the development of neurodegeneration. Trends Neurosci 26: 337-339, 2003.
82. Hegde RS, Mastrianni JA, Scott MR, Defea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, and Lingappa VR. A transmembrane form of the prion protein in neurode-generative disease. Science 279: 827-834, 1998.
83. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, and Lingappa VR. Transmissible and genetic prion diseases share a common pathway of neurodegeneration. Nature 402: 822-826, 1999.
84. Heller U, Winklhofer KF, Heske J, Reintjes A, and Tatzelt J. Post-translational import of the prion protein into the en-doplasmic reticulum interferes with cell viability: a critical role for the putative transmembrane domain. J Biol Chem 278: 36139-36147, 2003.
85. Herms J, Tings T, Gall S, Madlung A, Giese A, Siebert H, Schürmann P, Windl O, Brose N, and Kretzschmar H. Evidence of presynaptic location and function of the prion protein. J Neurosci 19: 8866-8875, 1999.
86. Hesketh S, Sassoon J, Knight R, and Brown DR. Elevated manganese levels in blood and CNS in human prion disease. Mol Cell Neurosci 37: 590-598, 2008.
87. Hesketh S, Sassoon J, Knight R, Hopkins J, and Brown DR. Elevated manganese levels in blood and central nervous system occur before onset of clinical signs in scrapie and bovine spongiform encephalopathy. J Anim Sci 85: 1596-1609, 2007.
88. Hetz C, Castilla J, and Soto C. Perturbation of endoplasmic reticulum homeostasis facilitates prion replication. J Biol Chem 282: 12725-12733, 2007.
89. Hetz CA and Soto C. Stressing out the ER: a role of the unfolded protein response in prion-related disorders. Curr Mol Med 6: 37-43, 2006.
90. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, and Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 36: 1304-1308, 2008.
91. C may inhibit prion disease propagation. Brain Res 12: 192-200, 2003.
92. Hill AF, Joiner S, Linehan J, Desbruslais M, Lantos PL, and Collinge J. Species-barrier-independent prion replication in apparently resistant species. Proc Natl Acad Sci USA 97: 10248-10253, 2000.
93. Hodak M, Chisnell R, Lu W, and Bernholc J. Functional implications of multistage copper binding to the prion protein. Proc Natl Acad Sci USA 106: 11576-11581, 2009.
94. Hornshaw MP, McDermott JR, and Candy JM. Copper binding to the N-terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res Com-mun 207: 621-629, 1995.
95. Hornshaw MP, McDermott JR, Candy JM, and Lakey JH. Copper binding to the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 214: 993-999, 1995.
96. Hutter G, Heppner FL, and Aguzzi A. No superoxide dismutase activity of cellular prion protein in vivo. Biol Chem 384: 1279-1285, 2003.
97. Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, Clarke AR, and Collinge J. Location and properties of metal-binding sites on the human prion protein. Proc Natl Acad Sci USA 98: 8531-8535, 2001.
98. Jeffrey M, Goodsir CM, Race RE, and Chesebro B. Scrapie-specific neuronal lesions are independent of neuronal PrP expression. Ann Neurol 55: 781-792, 2004.
99. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 344: 796-798, 1994.
100. Jeong SY and David S. Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 278: 27144-27148, 2003.
101. Jin T, Gu Y, Zanusso G, Sy M, Kumar A, Cohen M, Gam-betti P, and Singh N. The chaperone protein BiP binds to a mutant prion protein and mediates its degradation by the proteasome. J Biol Chem 275: 38699-38704, 2000.
102. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain C, Volitakis I, Perugini M, White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush AI, and Cappai R. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40: 8073-8084, 2001.
103. 2\+ coordination by His96 and His111 induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein. J Biol Chem 279: 32018-32027, 2004.
104. Kaplan J. Mechanisms of cellular iron acquisition: another iron in the fire. Cell 111: 603-606, 2002.
105. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boon-plueang R, Viswanath V, Jacobs R, Yang L, Beal MF, Di-Monte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, and Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 889-890, 2003.
106. KawanoT.Prion-derived copper-binding peptide fragments catalyze the generation of superoxide anion in the presence of aromatic monoamines. Int J Biol Sci 3: 57-63, 2007.
107. Kim BH, Jun YC, Jin JK, Kim JI, Kim NH, Leibold EA, Connor JR, Choi EK, Carp RI, and Kim YS. Alteration of iron regulatory proteins (IRP1 and IRP2) and ferritin in the brains of scrapie-infected mice. Neurosci Lett 422: 158-163, 2007.
108. Kim JI, Ju WK, Choi JH, Choi E, Carp RI, Wisniewski HM, and Kim YS. Expression of cytokine genes and increased nuclear factor-kappa B activity in the brains of scrapie-infected mice. Brain Res Mol Brain Res 73: 17-27, 1999.
109. Kim JL, Choi SI, Kim NH, Jin JK, Choi EK, Carp RI, and Kim, YS. Oxidative stress and neurodegeneration in prion diseases. Ann N Y Acad Sci 928: 182-186, 2001.
110. res. FASEB J 19: 783-785, 2005.
111. Kim NH, Park SJ, Jin JK, Kwon MS, Choi EK, Carp RI, and Kim YS. Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice. Brain Res 884: 98-103, 2000.
112. Klamt F, Dal-Pizzol F, Conte da Frota ML, Walz R, An-drades ME, da Silva EG, Brentani RR, Izquierdo I, and Fonseca Moreira JC. Imbalance of antioxidant defense in mice lacking cellular prion protein. Free Radic Biol Med 30: 1137-1144, 2001.
113. 2\+ binding modes of full-length prion protein. J Biol Chem 283: 1870-1881, 2008.
114. Kordek R, Nerurkar VR, Liberski PP, Isaacson S, Yanagi-hara R, and Gajdusek DC. Heightened expression of tumor necrosis factor alpha, interleukin 1 alpha, and glial fibrillary acidic protein in experimental Creutzfeldt-Jakob disease in mice. Proc Natl Acad Sci USA 93: 9754-9758, 1996.
115. Kovacs GG and Budka H. Prion diseases: from protein to cell pathology. Am J Pathol 172: 555-565, 2008.
116. Krasemann S, Zerr I, Weber T, Poser S, Kretzschmar H, Hunsmann G, and Bodemer W. Prion disease associated with a novel nine octapeptide repeat insertion in the PRNP gene. Mol Brain Res 34: 173-176, 1995.
117. Kretzschmar HA, Tings T, Madlung A, Giese A, and Herms J. Function of PrP(C) as a copper-binding protein at the synapse. Arch Virol Suppl 16: 239-249, 2000.
118. Kuczius T, Buschmann A, Zhang W, Karch H, Becker K, Peters G, and Groschup MH. Cellular prion protein acquires resistance to proteolytic degradation following copper ion binding. Biol Chem 385: 739-747, 2004.
119. Lasmézas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier J, and Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 275: 402-405, 1997.
120. Lasmézas CI. Putative functions of PrP(C). Br Med Bull 66: 61-70, 2003.
121. Leclerc E, Serban H, Prusiner SB, Burton DR, and Williamson RA. Copper induces conformational changes in the N-terminal part of cell-surface PrPC. Arch Virol 151: 2103-2109, 2006.
122. Lee KS, Magalhães AC, Zanata SM, Brentani RR, Martins VR, and Prado MA. Internalization of mammalian fluorescent cellular prion protein and N-terminal deletion mutants in living cells. J Neurochem 79: 79-87, 2001.
123. Lee KS, Raymond LD, Schoen B, Raymond GJ, Kett L, Moore RA, Johnson LM, Taubner L, Speare JO, Onwubiko HA, Baron GS, Caughey WS, and Caughey B. Hemin interactions and alterations of the subcellular localization of prion protein. J Biol Chem 282: 36525-36533, 2007.
124. Lee S and Eisenberg D. Seeded conversion of recombinant prion protein to a disulfide-bonded oligomer by a reduction-oxidation process. Nat Struct Biol 10: 725-730, 2003.
125. Lehmann S. Metal ions and prion diseases. Curr Opin Chem Biol 6: 187-192, 2002.
126. Linden R, Martins VR, Prado MA, Cammarota M, Iz-quierdo I, and Brentani RR. Physiology of the prion protein. Physiol Rev 88: 673-728, 2008.
127. Lledo PM, Tremblay P, DeArmond SJ, Prusiner SB, and Nicoll RA. Mice deficient for prion protein exhibit normal neuronal excitability and synaptic transmission in the hippocampus. Proc Natl Acad Sci USA 93: 2403-2407, 1996.
128. Llewelyn CA, Hewitt PE, Knight RSG, Amar K, Cousens S, Mackenzie J, and Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet 363: 417-421, 2004.
129. C). Mol Neurobiol 35: 236-244, 2007.
130. Sc-like conformation in the cytosol. Science 298: 1785-1788, 2002.
131. Ma J, Wollmann R, and Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298: 1781-1785, 2002.
132. MacKenzie EL, Iwasaki K, and Tsuji Y. Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid Redox Signal 10: 997-1030, 2001.
133. Madsen E and Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 30: 317-337, 2007.
134. Magalhães AC, Baron GS, Lee KS, Steele-Mortimer O, Dorward D, Prado MA, and Caughey B. Uptake and neu-ritic transport of scrapie prion protein coincident with infection of neuronal cells. J Neurosci 25: 5207-5216, 2005.
135. Malaisé M, Schätzl HM, and Bürkle A. The octarepeat region of prion protein, but not the TM1 domain, is important for the antioxidant effect of prion protein. Free Radic Biol Med 45: 1622-1630, 2008.
136. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, and Collinge J. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 302: 871-874, 2003.
137. Martin WR, Ye FQ, and Allen PS. Increasing striatal iron content associated with normal aging. Mov Disord 13: 281-286, 1998.
138. Mechoulam R, Panikashvili D, and Shohami E. Cannabi-noids and brain injury: therapeutic implications. Trends Mol Med 8: 58-61, 2002.
139. Melov S, Doctrow SR, Schneider JA, Haberson J, Patel M, Coskun PE, Huffman K, Wallace DC, and Malfroy B. Lifespan extension and rescue of spongiform encephalop-athy in superoxide dismutase 2 nullizygous mice treated with superoxide dismutase-catalase mimetics. J Neurosci 21: 8348-8353, 2001.
140. Milhavet O and Lehmann S. Oxidative stress and the prion protein in transmissible spongiform encephalopathies. Brain Res Brain Res Rev 38: 328-339, 2002.
141. Milhavet O, McMahon HE, Rachidi W, Nishida N, Kata-mine S, Mangé A, Arlotto M, Casanova D, Riondel J, Favier A, and Lehmann S. Prion infection impairs the cellular response to oxidative stress. Proc Natl Acad Sci USA 97: 13937-13942, 2000.
142. Millhauser GL. Copper and the prion protein: methods, structures, function, and disease. Annu Rev Phys Chem 58: 299-320, 2007.
143. Millhauser GL. Copper binding in the prion protein. Acc Chem Res 37: 79-85, 2004.
144. Mishra RS, Basu S, Gu Y, Luo X, Zou WQ, Mishra R, Li R, Chen SG, Gambetti P, Fujioka H, and Singh N. Protease-resistant human prion protein and ferritin are co-transported across Caco-2 epithelial cells: implications for species barrier in prion uptake from the intestine. J Neurosci 24: 11280-11290, 2004.
145. Mishra RS, Gu Y, Bose S, Verghese S, Kalepu S, and Singh N. Cell surface accumulation of a truncated transmembrane prion protein in Gerstmann-Straussler- Scheinker disease P102L. J Biol Chem 277: 24554-24561, 2002.
146. Miura T, Hori-I A, and Takeuchi H. Metal-dependent alpha-helix formation promoted by the glycine-rich octa-peptide region of prion protein. FEBS Lett 396: 248-252, 1996.
147. Miura T, Sasaki S, Toyama A, and Takeuchi H. Copper reduction by the octapeptide repeat region of prion protein: pH dependence and implications in cellular copper uptake. Biochemistry 44: 8712-8720, 2005.
148. Molina-Holgado F, Hider RC, Gaeta A, Williams R, and Francis P. Metals ions and neurodegeneration. Biometals 20: 639-654, 2007.
149. Moore RC, Mastrangelo P, Bouzamondo E, Heinrich C, Legname G, Prusiner SB, Hood L, Westaway D, DeArmond SJ, and Tremblay P. Doppel-induced cerebellar degeneration in transgenic mice. Proc Natl Acad Sci USA 98: 15288-15293, 2001.
150. Moos T and Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease. Ann N Y Acad Sci 1012: 14-26, 2004.
151. Muller WE, Laplane JL, Ushijima H, and Schroder HC. Novel approaches in diagnosis and therapy of Creutzfeldt-Jakob disease. Mech Ageing Dev 116: 193-218, 2000.
152. Murakami-Kubo I, Doh-Ura K, Ishikawa K, Kawatake S, Sasaki K, Kira J, Ohta S, and Iwaki T. Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J Virol 78: 1281-1288, 2004.
153. Murata M, Gong P, Suzuki K, and Koizumi S. Differential metal response and regulation of human heavy metal-inducible genes. J Cell Physiol 180: 105-113, 1999.
154. 2\+, but is a sacrificial quencher of hydroxyl radicals. Free Radic Biol Med 42: 79-89, 2007.
155. Nicolas O, Gavín R, and Del Ŕio JA. New insights into cellular prion protein (PrP(c)) functions: the "ying and yang" of a relevant protein. Brain Res Rev 61: 170-184, 2009.
156. Nishina K, Jenks S, and Supattapone SJ. Ionic strength and transition metals control PrPSc protease resistance and conversion-inducing activity. Biol Chem 279: 40788-40794, 2004.
157. Novitskaya V, Bocharova OV, Bronstein I, and Baskakov IV. Amyloid fibrils of mammalian prion protein are highly toxic to cultured cells and primary neurons. J Biol Chem 281: 13828-13836, 2006.
158. Olanow CW and Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 7: 548-558, 1994.
159. res amplification. J Neurochem 96: 1409-1415, 2006.
160. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, and Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20: 6048-6054, 2000.
161. Otto M, Copek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Perganda G, Ellers-Lenz B, Windl O, Ketzscldmar HA, Poser S, and Prange H. Efficacy of flu-pirtine on cognitive function in patients with CJD: a double blind study. Neurology 62: 714-718, 2004.
162. Pamplona R, Naudí A, Gavín R, Pastrana MA, Sajnani G, Ilieva EV, Del Ŕio JA, Portero-Otín M, Ferrer I, and Re-quena JR. Increased oxidation, glycoxidation, and lipox-idation of brain proteins in prion disease. Free Radic Biol Med 45: 1159-1166, 2008.
163. Pantopoulos K. Iron metabolism and the IRE=IRP regulatory system: an update. Ann N Y Acad Sci 1012: 1-13, 2004.
164. Park SJ, Kim NH, Jeong BH, Jin JK, Choi JK, Park YJ, Kim JI, Carp RI, and Kim YS. The effect of Fenton reaction on protease-resistant prion protein (PrPSc) degradation and scrapie infectivity. Brain Res 1238: 172-180, 2008.
165. Parkin ET, Watt NT, Turner AJ, and Hooper NM. Dual mechanisms for shedding of the cellular prion protein. J Biol Chem 279: 11170-11178, 2004.
166. Pauly PC and Harris DA. Copper stimulates endocytosis of the prion protein. J Biol Chem 273: 33107-33110, 1998.
167. Perera WS and Hooper NM. Ablation of the metal ion-induced endocytosis of the prion protein by disease-associated mutation of the octarepeat region. Curr Biol 11: 519-523, 2001.
168. Perovic S, Schröder HC, Pergande G, Ushijima H, and Müller WE. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP 106-126). Exp Neurol 147: 518-524, 1997.
169. Perry G, Taddeo MA, Petersen RB, Castellani RJ, Harris PL, Siedlak SL, Cash AD, Liu Q, Nunomura A, Atwood CS, and Smith MA. Adventitiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16: 77-81, 2003.
170. Peters PJ, Mironov A Jr, Peretz D, van Donselaar E, Leclerc E, Erpel S, DeArmond SJ, Burton DR, Williamson RA, Vey M, and Prusiner SB. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol 162: 703-717, 2003.
171. Petersen RB, Siedlak SL, Lee HG, Kim YS, Nunomura A, Tagliavini F, Ghetti B, Cras P, Moreira PI, Castellani RJ, Guentchev M, Budka H, Ironside JW, Gambetti P, Smith MA, and Perry G. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol (Berl) 110: 232-238, 2005.
172. Petrak JV and Vyoral D. Detection of iron-containing proteins contributing to the cellular labile iron pool by a native electrophoresis metal blotting technique. J Inorg Biochem 86: 669-675, 2001.
173. Piccardo P, Manson JC, King D, Ghetti B, and Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci USA 104: 4712-4717, 2007.
174. Pietri M, Caprini A, Mouillet-Richard S, Pradines E, Er-monval M, Grassi J, Kellermann O, and Schneider B. Overstimulation of PrPC signaling pathways by prion peptide 106-126 causes oxidative injury of bioaminergic neuronal cells. J Biol Chem 281: 28470-28479, 2006.
175. Pollera C, Lucchini B, Formentin E, Bareggi S, Poli G, and Ponti W. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet Res Commun 29: 253-255, 2005.
176. Prusiner SB. Prions. Proc Natl Acad Sci USA 95: 3363-3383, 1998.
177. Quaglio E, Chiesa R, and Harris DA. Copper converts the cellular prion protein into a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem 276: 11432-11438, 2001.
178. Race R, Raines A, Raymond GJ, Caughey B, and Chesebro B. Long-term subclinical carrier state precedes scrapie replication and adaptation in a resistant species: analogies to bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in humans. J Virol 75: 10106-10112, 2001.
179. Rachidi W, Chimienti F, Aouffen M, Senator A, Guiraud P, Seve M, and Favier A. Prion protein protects against zinc-mediated cytotoxicity by modifying intracellular exchangeable zinc and inducing metallothionein expression. J Trace Elem Med Biol 23: 214-223, 2009.
180. Rachidi W, Vilette D, Guiraud P, Arlotto M, Riondel J, Laude H, Lehmann S, and Favier A. Expression of prion protein increases cellular copper binding and antioxidant enzyme activities but not copper delivery. J Biol Chem 278: 9064-9072, 2003.
181. Ross CA and Poirier MA. Protein aggregation and neuro-degenerative disease. Nat Med 10(Suppl): S10-S17, 2004.
182. Roucou X and LeBlanc AC. Cellular prion protein neuro-protective function: implications in prion diseases. J Mol Med 83: 3-11, 2005.
183. Roucou X, Gains M, and LeBlanc AC. Neuroprotective functions of prion protein. J Neurosci Res 75: 153-161, 2004.
184. Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, and LeBlanc A. Cellular prion protein inhibits proa-poptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ 12: 783-795, 2005.
185. Roucou X, Guo G, Zhang Y, Goodyer CG, and LeBlanc AC. Cytosolic prion protein is not toxic and protects against Bax mediated cell death in human primary neurons. J Biol Chem 278: 40877-40881, 2003.
186. Ruiz FH, Silva E, and Inestrosa NC. The N-terminal tandem repeat region of human prion protein reduces copper: role of tryptophan residues. Biochem Biophys Res Commun 269: 491-495, 2000.
187. Sakaguchi S, Katamine S, Nishida N, Moriuchi R, Shige-matsu K, Sugimoto T, Nakatani A, Kataoka Y, Houtani T, Shirabe S, Okada H, Hasegawa S, Miyamoto T, and Noda T. Loss of cerebellar Purkinje cells in aged mice homozy-gous for a disrupted PrP gene. Nature 380: 528-531, 1996.
188. Sakudo A, Lee DC, Saeki K, Nakamura Y, Inoue K, Mat-sumoto Y, Itohara S, and Onodera T. Impairment of su-peroxide dismutase activation by N-terminally truncated prion protein (PrP) in PrP-deficient neuronal cell line. Bio-chem Biophys Res Commun 308: 660-667, 2003.
189. Sakudo A, Lee DC, Yoshimura E, Nagasaka S, Nitta K, Saeki K, Matsumoto Y, Lehmann S, Itohara S, Sakaguchi S, and Onodera T. Prion protein suppresses perturbation of cellular copper homeostasis under oxidative conditions. Biochem Biophys Res Commun 313: 850-855, 2004.
190. Sakudo A, Nakamura I, Tsuji S, and Ikuta K. GPI-anchor-less human prion protein is secreted and glycosylated but lacks superoxide dismutase activity. Int J Mol Med 2: 217-222, 2008.
191. Sakudo A, Onodera T, Suganuma Y, Kobayashi T, Saeki K, and Ikuta K. Recent advances in clarifying prion protein functions using knockout mice and derived cell lines. Mini Rev Med Chem 6: 589-601, 2006.
192. Schipper HM. Brain iron deposition and the free radical-mitochondrial theory of ageing. Ageing Res Rev 3: 265-301, 2004.
193. (Erratum in Ageing Res Rev 5: 117-118, 2006).
194. Schneider B, Mutel V, Pietri M, Ermonval M, Mouillet-Richard S, and Kellermann O. NADPH oxidase and extracellular regulated kinases 1=2 are targets of prion protein signaling in neuronal and nonneuronal cells. Proc Natl Acad Sci USA 100: 13326-13331, 2003.
195. Schroder HC and Muller WE. Neuroprotective effect of flupirtine in prion disease. Drugs Today (Barc) 38: 49-55, 2002.
196. Shearer J, Soh P, and Lentz S. Both Met(109) and Met(112) are utilized for Cu(II) coordination by the amyloidogenic fragment of the human prion protein at physiological pH. J Inorg Biochem 102: 2103-2113, 2008.
197. Shearer J and Soh P. The copper (II) adduct of the unstructured region of the amyloidogenic fragment derived from the human prion protein is redox-active at physiological pH. Inorg Chem 46: 710-719, 2007.
198. Shi S, Dong CF, Tian C, Zhou RM, Xu K, Zhang BY, Gao C, Han J, and Dong XP. The propagation of hamster-adapted scrapie PrPSc can be enhanced by reduced pyridine nu-cleotide in vitro. FEBS J 276: 1536-1545, 2009.
199. Shiraishi N, Ohta Y, and Nishikimi M. The octapeptide repeat region of prion protein binds Cu(II) in the redox-inactive state. Biochem Biophys Res Commun 267: 398-402, 2000.
200. Shmerling D, Hegyi I, Fischer M, Blättler T, Brandner S, Götz J, Rülicke T, Flechsig E, Cozzio A, von Mering C, Hangartner C, Aguzzi A, and Weissmann C. Expression of amino-terminally truncated PrP in the mouse leading to ataxia and specific cerebellar lesions. Cell 93: 203-214, 1998.
201. Shyng SL, Moulder KL, Lesko A, and Harris DA. The N-terminal domain of a glycolipid-anchored prion protein is essential for its endocytosis via clathrin-coated pits. J Biol Chem 270: 14793-14800, 1995.
202. Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, and Wisniewski T. Copper chelation delays the onset of prion disease. J Biol Chem 278: 46199-46202, 2003.
203. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, and Caughey B. The most infectious prion protein particles. Nature 437: 257-261, 2005.
204. Singh A, Isaac AO, Luo X, Mohan ML, Cohen ML, Chen F, Kong Q, Bartz J, and Singh N. Abnormal brain iron ho-meostasis in human and animal prion disorders. PloS Pa-thog 5: e1000336, 2009.
205. Singh A, Kong Q, Luo X, Petersen RB, and Meyerson H. Singh N. Prion protein (PrP) knock-out mice show altered iron metabolism: a functional role for PrP in iron uptake and transport. PLoS One 4: e6115, 2009.
206. Singh A, Mohan ML, Isaac AO, Luo X, and Singh N. Prion protein modulates cellular iron metabolism: implications for prion disease pathogenesis. PloS One 4: e4468, 2009.
207. Smith DG, Cappai R, and Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Bio-chim Biophys Acta 1768: 1976-1990, 2007.
208. Smith MA, Harris PL, Sayre LM, and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868, 1997.
209. Sohal RS, Wennberg-Kirch E, Jaiswal K, Kwong LK, and Forster MJ. Effect of age and caloric restriction on bleo-mycin-chelatable and nonheme iron in different tissues of C57BL=6 mice. Free Radic Biol Med 27: 287-293, 1999.
210. Solforosi L, Criado JR, McGavern DB, Wirz S, Sánchez-Alavez M, Sugama S, DeGiorgio LA, Volpe BT, Wiseman E, Abalos G, Masliah E, Gilden D, Oldstone MB, Conti B, and Williamson RA. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science 303: 1514-1516, 2004.
211. Spudich A, Frigg R, Kilic E, Kilic U, Oesch B, Raeber A, Bassetti CL, and Hermann DM. Aggravation of ischemic brain injury by prion protein deficiency: role of ERK-1=-2 and STAT-1. Neurobiol Dis 20: 442-449, 2005.
212. Stevens DJ, Walter ED, Rodríguez A, Draper D, Davies P, Brown DR, and Millhauser GL. Early onset prion disease from octarepeat expansion correlates with copper binding properties. PLoS Pathog 5: e1000390, 2009.
213. Stöckel J, Safar J, Wallace AC, Cohen FE, and Prusiner SB. Prion protein selectively binds copper(II) ions. Biochemistry 20: 7185-7193, 1998.
214. Strausak D, Mercer JF, Dieter HH, Stremmel W, and Mul-thaup G. Copper in disorders with neurological symptoms: Alzheimer's, Menkes, and Wilson diseases. Brain Res Bull 55: 175-185, 2001.
215. Suh JH, Moreau R, Heath SH, and Hagen TM. Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxi-dants in the rat cerebral cortex. Redox Rep 10: 52-60, 2005.
216. Tabner BJ, Turnbull S, Fullwood NJ, German M, and Allsop D. The production of hydrogen peroxide during early-stage protein aggregation: a common pathological mechanism in different neurodegenerative diseases? Biochem Soc Trans 33: 548-550, 2005.
217. Taylor DR, Watt NT, Perera WS, and Hooper NM. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J Cell Sci 118: 5141-5153, 2005.
218. Telling GC, Haga T, Torchia M, Tremblay P, DeArmond SJ, and Prusiner SB. Interactions between wild-type and mutant prion proteins modulate neurodegeneration in trans-genic mice. Genes Dev 10: 1736-1750, 1996.
219. Texel SJ, Xu X, and Harris ZL. Ceruloplasmin in neurode-generative diseases. Biochem Soc Trans 36: 1277-1281, 2008.
220. Thackray AM, Knight R, Haswell SJ, Bujdoso R, and Brown DR. Metal imbalance and compromised antioxidant function are early changes in prion disease. Biochem J 362: 253-258, 2002.
221. Thompson KJ, Shoham S, and Connor JR. Iron and neu-rodegenerative disorders. Brain Res Bull 55: 155-164, 2001.
222. Thomzig A, Schulz-Schaeffer W, Wrede A, Wemheuer W, Brenig B, Kratzel C, Lemmer K, and Beekes M. Accumulation of pathological prion protein PrPSc in the skin of animals with experimental and natural scrapie. PLoS Pathog 3: e66, 2007.
223. Tobler I, Gaus SE, Deboer T, Achermann P, Fischer M, Rulicke T, Moser M, Oesch B, McBride PA, and Manson JC. Altered circadian activity rhythms and sleep in mice devoid of prion protein. Nature 380: 639-642, 1996.
224. Toni M, Massimino ML, Griffoni C, Salvato B, Tomasi V, and Spisni E. Extracellular copper ions regulate cellular prion protein (PrPC) expression and metabolism in neu-ronal cells. FEBS Lett 579: 741-744, 2005.
225. Turnbull S, Tabner BJ, Brown DR, and Allsop D. Copper-dependent generation of hydrogen peroxide from the toxic prion protein fragment PrP106-126. Neurosci Lett 336: 159-162, 2003. (Pubitemid 36044603)
226. Turnbull S, Tabner BJ, Brown DR, and Allsop D. Generation of hydrogen peroxide from mutant forms of the prion protein fragment PrP121-231. Biochemistry 42: 7675-7681, 2003. (Pubitemid 36758932)
227. Varela-Nallar L, Toledo EM, Chacón MA, and Inestrosa NC. The functional links between prion protein and copper. Biol Res 39: 39-44, 2006.
228. Varela-Nallar L, Toledo EM, Larrondo LF, Cabral AL, Martins VR, and Inestrosa NC. Induction of cellular prion protein gene expression by copper in neurons. Am J Physiol Cell Physiol 290: C271-C281, 2005.
229. Vassallo N and Herms J. Cellular prion protein function in copper homeostasis and redox signalling at the synapse J Neurochem 86: 538-544, 2003.
230. Vilette D. Cell models of prion infection. Vet Res 39: 10, 2008.
231. Wadsworth JDF, Hill AF, Joiner S, Jackson GS, Clarke AR, and Collinge J. Strain specific prion protein conformation determined by metal ions. Nat Cell Biol 1: 55-59, 1999.
232. Waggoner DJ, Drisaldi B, Bartnikas TB, Casareno RL, Prohaska JR, Gitlin JD, and Harris DA. Brain copper content and cuproenzyme activity do not vary with prion protein expression level. J Biol Chem 275: 7455-7458, 2000.
233. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi ME, Britton RS, Bacon BR, and Sly WS. Regulation of transferrin-mediated iron uptake by HFE, the protein defective in hereditary hemochromatosis. Proc Natl Acad Sci USA 99: 3117-3122, 2002.
234. 2\+ coordination modes. J Am Chem Soc 129: 15440-15441, 2007.
235. Watt NT and Hooper NM. Reactive oxygen species (ROS)-mediated beta-cleavage of the prion protein in the mechanism of the cellular response to oxidative stress. Biochem Soc Trans 33: 1123-1125, 2005.
236. Watt NT and Hooper NM. The prion protein and neuronal zinc homeostasis. Trends Biochem Sci 28: 406-410, 2003.
237. Watt NT, Taylor DR, Gillott A, Thomas DA, Perera WS, and Hooper NM. Reactive oxygen species-mediated beta-cleavage of the prion protein in the cellular response to oxidative stress. J Biol Chem 280: 35914-35921, 2005.
238. Watts JC, Balachandran A, and Westaway D. The expanding universe of prion diseases. PLoS Pathog 2: e26, 2006.
239. C) after focal cerebral ischemia and influence of lesion severity. Neurosci Lett 372: 146-150, 2004.
240. Westergard L, Christensen HM, and Harris DA. The cellular prion protein (PrP(C)): its physiological function and role in disease. Biochim Biophys Acta 1772: 629-644, 2007.
241. White AR, Collin SJ. Maher F, Jobling MF, Stewart LR, Thyer JM, Beyreuther K, Masters CL, and Cappai R. Prion protein-deficient neurons reveal lower glutathione reduc-tase activity and increased susceptibility to hydrogen peroxide toxicity. Am J Pathol 155: 1723-1730, 1999.
242. Whittal RM, Ball HL, Cohen FE, Burlingame AL, Prusiner SB, and Baldwin MA. Copper binding to octarepeat pep-tides of the prion protein monitored by mass spectrometry. Protein Sci 9: 332-343, 2000.
243. Wong BS, Brown DR, Pan T, Whiteman M, Liu T, Bu X, Li R, Gambetti P, Olesik J, Rubenstein R, and Sy MS. Oxidative impairment in scrapie-infected mice is associated with brain metals perturbations and altered antioxidant activities, J Neurochem 79: 689-698, 2001.
244. Wong BS, Chen SG, Colucci M, Xie Z, Pan T, Liu T, Li R, Gambetti P, Sy MS, and Brown DR. Aberrant metal binding by prion protein in human prion disease. J Neurochem 78: 1400-1408, 2001.
245. Wong BS, Liu T, Li R, Pan T, Petersen RB, Smith MA, Gambetti P, Perry G, Manson JC, Brown DR, and Sy MS. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. J Neurochem 76: 565-572, 2001.
246. Wong BS, Pan T, Liu T, Li R, Petersen RB, Jones IM, Gambetti P, Brown DR, and Sy MS. Prion disease: a loss of antioxidant functions? Biochem Biophys Res Commun 275: 249-252, 2000.
247. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, Chesebro B, and Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J 20: 377-386, 2001.
248. Yoo HY, Chang MS, and Rho HM. Heavy metal-mediated activation of the rat Cu=Zn superoxide dismutase gene via a metal-responsive element. Mol Gen Genet 262: 310-313, 1999.
249. Youdim MB, Stephenson G, and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurodegenera-tive diseases with iron chelators: a lesson from 6-hydro-xydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012: 306-325, 2004.
250. Yun SW, Gerlach M, Riederer P, and Klein MA. Oxidative stress in the brain at early preclinical stages of mouse scrapie. Exp Neurol 201: 90-98, 2006.
251. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, and Zucca FA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101: 9843-9848, 2004.
252. Zecca L, Youdim MBH, Riederer P, Connor JR and Crich-ton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873, 2004.
253. Zhu X, Su B, Wang X, Smith MA, and Perry G. Causes of oxidative stress in Alzheimer disease. Cell Mol Life Sci 64: 2202-2210, 2007. (Pubitemid 47347959)
254. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MBH, and Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844, 2007